The BNIP3L Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphoblastoid line, designed to disrupt expression of BNIP3L (NIX). This polyclonal loss-of-function model maintains genetic diversity, enabling unbiased functional genomics studies of mitophagy and apoptosis in T-cell leukemia contexts.
Jurkat cells were derived from the peripheral blood of a 14-year-old boy with acute T-cell leukemia and are an immortalized T lymphoblastoid cell line. They are extensively used to study T-cell antigen receptor signaling, apoptosis, and leukemogenesis, providing a robust and reproducible model for T-cell biology and cancer research.
BNIP3L (NIX) is a pro-apoptotic BH3-only protein that serves as a selective receptor for mitochondrial autophagy (mitophagy). Its expression is upregulated under hypoxia by transcription factors HIF1A, TP53, FOXO3, and coactivator PPARGC1A, while mTOR signaling provides additional regulatory input. BNIP3L directly interacts with ATG8 family members (MAP1LC3A, MAP1LC3B, GABARAP) via an LIR motif, linking damaged mitochondria to autophagosomal membranes for lysosomal degradation. Concurrently, BNIP3L sequesters anti-apoptotic BCL2 and BCL2L1, derepressing BAX and BAK to permeabilize the mitochondrial outer membrane, releasing cytochrome c and activating caspases-9 and -3. This dual functionality positions BNIP3L as a critical integrator of cellular stress responses, connecting HIF-1 signaling, autophagy, and intrinsic apoptosis.
In Jurkat T-cell leukemia cells, BNIP3L knockout ablates a central mediator of hypoxia-induced mitophagy and apoptosis, making this model ideal for investigating mitochondrial quality control defects associated with hematologic malignancies. The polyclonal population facilitates studies of BNIP3L’s roles in T-cell survival, drug resistance, and differentiation, with relevance to myelodysplastic syndromes, erythropoiesis defects, and ischemic disease pathways.
Researchers can utilize these cells for Western blotting, flow cytometry with MitoTracker and Annexin V, mitophagy flux assays (mt-Keima, LC3-II/p62 quantification), co-immunoprecipitation of BNIP3L with LC3 or BCL2, RT-qPCR, RNA-seq, Seahorse metabolic analysis, BH3 profiling, and drug sensitivity screening using venetoclax or hypoxia mimetics. These applications enable detailed dissection of hypoxia response, autophagy regulation, and apoptosis in T-cell leukemia. For further information, please contact Ascent Research.
